Long COVID is an often debilitating illness that occurs in at least 10% of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.

The efficacy of the BNT162b2 vaccine in pediatrics was assessed by randomised trials before the Omicron variant’s emergence.

The efficacy of simvastatin in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear.

Respiratory syncytial virus (RSV) can cause substantial morbidity and mortality among older adults.

Previous comparative analyses of people admitted to hospital for COVID-19 versus influenza evaluated the risk of death, hospital readmission, and a narrow set of health outcomes up to 6 months following infection.

The NIRSE-GAL study shows in real time the evolution of the coverage achieved by immunisation with Nirsevimab in children and compares RSV admissions in different population groups of children and adults in Galicia in Spain with previous years.

Protecting infants from RSV with new tools: vaccines for pregnant women and use of monoclonal antibodies have been approved for use in the European Union to prevent RSV among young children. Are those tools working?

Among 232 mechanically ventilated COVID-19 patients, 21.1% had known diabetes mellitus, whereas 16.9% in wave 2 had unknown diabetes mellitus.

Accurate information on the health burden of vaccine-preventable infections (VPIs) is needed to support evidence-informed vaccine policy recommendations and programmes in Europe.

People can be at risk of getting and spreading serious vaccine-preventable infectious diseases throughout their lives and can therefore benefit from a lifelong approach to vaccination.

Vaccines that protect against any H1N1 influenza A virus strain would beadvantageous for use in pigs and humans.